| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | IPR1; VODI; IFI41; IFI75 |
| WB Predicted band size | 78 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human SP110 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于SP110抗体的3篇参考文献摘要整理：
1. **《SP110基因多态性与结核病易感性的关联研究》**
- 作者：Zhang Y, et al.
- 摘要：通过免疫组化与Western blot分析，研究SP110蛋白在结核病患者巨噬细胞中的表达差异，发现SP110抗体检测显示其表达水平与宿主抗分枝杆菌免疫反应显著相关。
2. **《SP110调控干扰素信号通路的机制探索》**
- 作者：Boukhaled GM, et al.
- 摘要：利用SP110特异性抗体进行染色质免疫沉淀(ChIP)，揭示SP110通过结合干扰素调控因子(IRF)增强抗病毒基因转录，证实其在先天免疫中的关键作用。
3. **《SP110缺失对肝炎病毒感染的影响》**
- 作者：Li Q, et al.
- 摘要：通过抗体介导的SP110蛋白功能抑制实验，发现SP110缺失会削弱肝细胞对丙型肝炎病毒的清除能力，提示其作为潜在抗病毒治疗靶点。
4. **《SP110在系统性红斑狼疮中的表观遗传调控》**
- 作者：Wang H, et al.
- 摘要：采用SP110抗体进行患者外周血单核细胞免疫荧光分析，发现SP110表达异常与DNA甲基化修饰紊乱相关，可能参与自身免疫疾病的发展。
注：以上为虚拟文献，实际研究中建议通过PubMed或Google Scholar以关键词"SP110 antibody"+"immune"/"tuberculosis"/"mechanism"检索近期论文，并优先选择功能验证类研究。
The SP110 antibody targets the SP110 protein, a nuclear body protein encoded by the *SP110* gene. SP110 belongs to the SP100 family, known for roles in transcriptional regulation and innate immunity. It is implicated in antiviral defense, chromatin remodeling, and cell differentiation. Structurally, SP110 contains a SAND domain (involved in DNA binding), a PHD finger (linked to chromatin modification), and a bromodomain (acetyl-lysine recognition), suggesting its involvement in epigenetic regulation.
SP110 gained attention due to its association with human diseases. Studies link *SP110* polymorphisms to susceptibility to tuberculosis (TB), highlighting its role in immune responses against *Mycobacterium tuberculosis*. Additionally, SP110 dysregulation is observed in cancers, particularly acute myeloid leukemia (AML), where it may act as a tumor suppressor or oncogene depending on context.
Antibodies against SP110 are critical tools for detecting its expression, localization, and post-translational modifications in research. They are used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to study SP110's role in immune pathways, host-pathogen interactions, and cancer biology. Commercial SP110 antibodies are typically validated in human and mouse models, aiding mechanistic studies in infectious and neoplastic diseases. Ongoing research explores SP110 as a potential biomarker or therapeutic target, emphasizing its dual relevance in immunology and oncology.
×
